5-Fluoro-1-methyl-3-(2-methylpropyl)indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Fluoro-1-methyl-3-(2-methylpropyl)indole
• 英文别名: 5-fluoro-1-methyl-3-(2-methylpropyl)indole
• 化学式: C₁₃H₁₆FN
• 分子量: 205.27
• InChiKey: OLSDYLULZPSNAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] MALIC ENZYME INHIBITORS<br/>[FR] INHIBITEURS D'ENZYME MALIQUE
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2021074898A1

  公开（公告）日：2021-04-22

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

  本发明涉及一种新型化合物，可用作苹果酸酶（ME）抑制剂，以及用于制备这些化合物的方法和利用这些化合物治疗由ME介导的疾病，如人类的癌症（例如胰腺导管腺癌（PDAC））。
• Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease
  申请人：College of Medicine Philadelphia Health & Education Corporation d/b/a Drexel University

  公开号：US20140228355A1

  公开（公告）日：2014-08-14

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

  本发明提供了一种方法，用于抑制、抑制或预防帕金森病患者的左旋多巴诱发的运动障碍，包括向患者给予至少一种本发明化合物的药物组合物。本发明还提供了一种方法，用于抑制、抑制或预防帕金森病患者的病情，包括向患者给予至少一种本发明化合物的药物组合物。
• Malic enzyme inhibitors
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US11225480B2

  公开（公告）日：2022-01-18

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.

  本发明涉及可用作苹果酸酶（ME）抑制剂的新型化合物、其制备工艺以及这些化合物用于治疗由ME介导的疾病，如人类癌症（如胰腺导管腺癌（PDAC））。这些新型化合物具有符合式 I 的结构 或其药学上可接受的盐、立体异构体或氚代类似物，其中 X、R1、R2 和 Y 如本文所述。
• NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER
  申请人：DREXEL UNIVERSITY

  公开号：US20160256417A1

  公开（公告）日：2016-09-08

  The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.
• NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE
  申请人：DREXEL UNIVERSITY

  公开号：US20170246128A1

  公开（公告）日：2017-08-31

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.